← Back to all trials
Recruiting
NCT05024175
Long-term Follow-up of Subjects Treated With CAR T Cells
Conditions: Long Term Adverse Effects, CAR-T, Duty to Follow Up, Adult, Progression-Free Survival, Disease-Free Survival, Overall Survival
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 45
Sponsor: Marcela V. Maus, M.D.,Ph.D.
Location: Massachusetts General Hospital Boston Massachusetts
Summary
This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (HCC# 22-175), NCT06026319 (HCC# 23-474) and NCT NCT07388277 (MGB# 2025P003179.
Eligibility Criteria
Inclusion Criteria:
Subjects will be asked to participate leading up to the last HCC or MGB corresponding main study visit.
Subjects meeting the following criteria are eligible for study participation:
* Provision of voluntary written informed consent by subject
* CAR T cells were administered in HCC IRB or MGB IRB corresponding main study
Exclusion Criteria:
Subjects meeting the following criterion are to be excluded from study participation:
\- Subject unable to comply with study requirements
Source: ClinicalTrials.gov (NCT05024175). StuddyBuddy aggregates publicly available trial information.
